Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
Anti-PD-1 antibody
Cemiplimab
Libtayo · CEMI
An anti-PD-1 antibody with the checkpoint-class signature of immune-mediated acute interstitial nephritis.
ModerateImmune checkpoint inhibitor (anti-PD-1) · approved 2018
Advanced cutaneous squamous cell carcinomaAdvanced basal cell carcinomaNon-small cell lung cancer
Signature kidney injury
Acute Interstitial Nephritis
Follows the PD-1/PD-L1 class profile: any AKI in roughly 15-17% of patients, with immune-related AIN in a smaller clinically significant subset. As an anti-PD-1 agent it may carry somewhat higher AKI risk than anti-PD-L1 agents, and pharmacovigilance data show an immune-nephropathy signal; cemiplimab-specific renal incidence is not separately quantified.
Source: Meraz-Munoz et al., J Immunother Cancer 2020 (class-level any-AKI; agent-specific AIN rate not separately quantified)
Mechanism of kidney injury
PD-1 blockade breaks tubulointerstitial tolerance, producing T-cell-mediated acute (often granulomatous) interstitial nephritis, frequently potentiated by haptenizing co-medications (PPIs, NSAIDs); immune-mediated glomerular lesions occur less often.
Clinical presentation
Subacute creatinine rise, sterile pyuria, white-cell casts, sub-nephrotic proteinuria; commonly with extrarenal immune-related adverse events. Eosinophilia variable.
Onset
Weeks to months after initiation.
Reversibility
Partially reversible
Anticancer mechanism
Human IgG4 monoclonal antibody blocking the PD-1 receptor on T cells, reversing tumor-induced T-cell exhaustion. Used in advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
Management
Hold cemiplimab, exclude prerenal/obstructive and other causes, and treat immune-related AIN with corticosteroids (prednisone ~0.5-1 mg/kg/day with taper); partial-to-full recovery is common, with additional immunosuppression for steroid-refractory disease. Individualize rechallenge after recovery.
Risk factors
- Concurrent PPIs/NSAIDs and other AIN-associated drugs
- Combination immunotherapy
- Lower baseline kidney function
- Other concurrent immune-related adverse events
Prevention
- Serial creatinine monitoring
- Deprescribe unnecessary AIN-associated medications
- Early evaluation/biopsy for unexplained AKI
Note · Renal toxicity is a PD-1/PD-L1 class effect; cited incidence figures are class-level. Dedicated single-agent cemiplimab renal case reports are scarce, so attribution rests primarily on class data and pharmacovigilance signals.
Clinical depth
Renal dose adjustment
No baseline renal dose adjustment (fixed-dose antibody, not renally cleared). Toxicity-based modification follows irAE grading: withhold for grade 2 nephritis with steroids; permanently discontinue for grade 3-4 or recurrent severe nephritis.
Dialyzability & ESKD dosing
Not dialyzable—IgG4 monoclonal antibody cleared by reticuloendothelial catabolism; not removed by hemodialysis, no supplemental dosing, standard dosing in ESKD.
Differential diagnosis
Distinguish ICI-AIN (late, sterile pyuria, WBC casts, concurrent irAEs, steroid-responsive) from prerenal azotemia, obstruction, and other drug AIN; cystatin C and urine AIN biomarkers (TNF-alpha, IL-9, CXCL9) help confirm AIN and exclude pseudo-AKI. Heavy proteinuria/hematuria suggests a glomerular variant requiring biopsy.
Monitoring
- Serum creatinine/eGFR before each cycle
- Urinalysis with protein quantification and microscopy if creatinine rises
- Surveillance for concurrent irAEs
Key trials & series
- Cortazar JASN 2020 multicenter ICI-AKI cohort (class)
- Gupta J Immunother Cancer 2021 multicenter ICI-AKI cohort (class)
- Lima Immunopharmacol Immunotoxicol 2024 anti-PD-1 vs anti-PD-L1 AKI meta-analysis
Clinical pearls
- As an anti-PD-1 agent, cemiplimab may carry a slightly higher AKI risk than the anti-PD-L1 antibodies.
- Manage on class principles—biopsy atypical cases since agent-specific data are thin.
- A co-prescribed PPI is a frequent co-trigger; deprescribe during the AKI workup.
- Urine biomarkers and cystatin C help separate true AIN from pseudo-AKI before steroids.
Where it strikes
Nephron segments
Interstitium
Supporting tissue around the tubules
Glomerulus
Filtration barrier (podocytes + endothelium)
Injury signatures
Acute Interstitial NephritisGlomerular Injury / Proteinuria
Beyond the kidney
Class-level context for the major non-renal toxicities of anti-pd-1 antibodys.
Endocrine
Thyroiditis, hypophysitis, diabetes
- Thyroiditis, hypophysitis, type-1 diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Immune colitis
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Immune hepatitis
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pneumonitis
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Rash, vitiligo, rarely SJS/TEN
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkClinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.Cortazar FB et al. · Kidney Int 2016 · PMID 27282937Defining biopsy series of checkpoint-inhibitor-associated acute interstitial nephritis.PMIDClinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.Cortazar FB et al. · J Am Soc Nephrol 2020 · PMID 31896554Multicenter cohort defining ICI-AKI features, steroid response, and outcomes.PMIDAcute kidney injury in patients treated with immune checkpoint inhibitors.Gupta S et al. · J Immunother Cancer 2021 · PMID 34625513Large multicenter ICI-AKI cohort characterizing risk factors and recovery.PMIDImmune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?Perazella MA et al. · Kidney Int 2019 · PMID 31685311Core mechanism/management review of ICI nephrotoxicity.PMIDAcute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.Lima IG et al. · Immunopharmacol Immunotoxicol 2024 · PMID 38825890Meta-analysis comparing AKI risk across anti-PD-1 (including cemiplimab) and anti-PD-L1 agents.PMIDAcute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.Meraz-Munoz A et al. · J Immunother Cancer 2020 · PMID 32601079Cohort quantifying checkpoint-inhibitor AKI incidence and outcomes.PMIDSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.Brahmer JR et al. · J Immunother Cancer 2021 · PMID 34172516Consensus management guidance for renal and other immune-related adverse events.